Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study

Sangamo Therapeutics Inc SGMO, which developed a treatment in collaboration with Pfizer Inc PFE, received a boost to its stock price after struggling with liquidity issues.At last check Wednesday, Sangamo was up more than 36.2%, trading at 55 cents per share.Both companies released results from the Phase 3 AFFINE study of giroctocogene fitelparvovec, an investigational gene therapy for adult patients with moderately severe to severe hemophilia A.The AFFINE study achieved its primary objective.Also Read: Sec ...